Skip to Content

Generic Mektovi Availability

Medically reviewed by Drugs.com. Last updated on May 11, 2021.

Mektovi is a brand name of binimetinib, approved by the FDA in the following formulation(s):

MEKTOVI (binimetinib - tablet;oral)

  • Manufacturer: ARRAY BIOPHARMA INC
    Approval date: June 27, 2018
    Strength(s): 15MG [RLD]

Has a generic version of Mektovi been approved?

No. There is currently no therapeutically equivalent version of Mektovi available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mektovi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Compounds and compositions as protein kinase inhibitors
    Patent 10,005,761
    Issued: June 26, 2018
    Assignee(s): Array BioPharma Inc.

    The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

    Patent expiration dates:

    • August 27, 2030
      ✓ 
      Patent use: INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA
  • N3 alkylated benzimidazole derivatives as MEK inhibitors
    Patent 7,777,050
    Issued: August 17, 2010
    Inventor(s): Wallace; Eli M. & Lyssikatos; Joseph P. & Marlow; Allison L. & Hurley; T. Brian
    Assignee(s): Array BioPharma Inc.

    Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.

    Patent expiration dates:

    • March 13, 2023
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • N3 alkylated benzimidazole derivatives as MEK inhibitors
    Patent 8,178,693
    Issued: May 15, 2012
    Inventor(s): Wallace; Eli M. & Lyssikatos; Joseph P. & Marlow; Allison L. & Hurley; T. Brian
    Assignee(s): Array Biopharma Inc.

    Disclosed are compounds of the Formula and pharmaceutically acceptable salts and prodrugs thereof, wherein A, R1, R2, R7, R8, and R9 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.

    Patent expiration dates:

    • March 13, 2023
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors
    Patent 8,193,229
    Issued: June 5, 2012
    Inventor(s): Wallace; Eli M. & Lyssikatos; Joseph P. & Marlow; Allison L. & Hurley; T. Brian
    Assignee(s): Array Biopharma Inc.

    Disclosed are methods of treating a hyperproliferative disorder or a disease related to vasculogenesis or angiogenesis in a mammal, comprising administering to said mammal an effective amount of a compound of the formula or a pharmaceutically accepted salt thereof, wherein A, R1, R2, R7, R8, and R9 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals.

    Patent expiration dates:

    • March 13, 2023
      ✓ 
      Patent use: METHOD OF TREATING MELANOMA
  • Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal
    Patent 8,513,293
    Issued: August 20, 2013
    Assignee(s): Array BioPharma Inc.

    Disclosed are methods for inhibiting abnormal cell growth or treating hyperproliferative diseases in mammals, comprising administering to a mammal in heed thereof a pharmaceutical composition comprising 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of an anti-tumor agent or in combination with radiation therapy.

    Patent expiration dates:

    • March 13, 2023
      ✓ 
      Patent use: INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA
  • Compounds and compositions as protein kinase inhibitors
    Patent 9,314,464
    Issued: April 19, 2016
    Assignee(s): Novartis AG

    The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

    Patent expiration dates:

    • July 4, 2031
      ✓ 
      Patent use: INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
  • Preparation of and formulation comprising a MEK inhibitor
    Patent 9,562,016
    Issued: February 7, 2017
    Assignee(s): Array BioPharma, Inc. Novartis AG

    The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.

    Patent expiration dates:

    • October 18, 2033
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Compounds and compositions as protein kinase inhibitors
    Patent 9,593,100
    Issued: March 14, 2017
    Assignee(s): Array BioPharma, Inc.

    The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

    Patent expiration dates:

    • August 27, 2030
      ✓ 
      Drug product
  • Preparation of and formulation comprising a MEK inhibitor
    Patent 9,598,376
    Issued: March 21, 2017
    Assignee(s): Array BioPharma, Inc. Novartis AG

    The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro -3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.

    Patent expiration dates:

    • October 18, 2033
      ✓ 
      Patent use: METHOD OF TREATING MELANOMA
  • Compounds and compositions as protein kinase inhibitors
    Patent 9,850,229
    Issued: December 26, 2017
    Assignee(s): Array BioPharma, Inc.

    The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

    Patent expiration dates:

    • August 27, 2030
      ✓ 
      Patent use: INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
  • Preparation of and formulation comprising a MEK inhibitor
    Patent 9,980,944
    Issued: May 29, 2018
    Assignee(s): Array BioPharma Inc.

    The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.

    Patent expiration dates:

    • October 18, 2033
      ✓ 
      Patent use: TREATMENT OF MELANOMA WITH A BRAF MUTATION

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • June 27, 2023 - NEW CHEMICAL ENTITY
    • June 27, 2025 -

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.